key: cord-1014298-ccdw3r99
authors: Morel, Olivier; Marchandot, Benjamin; Jesel, Laurence; Sattler, Laurent; Trimaille, Antonin; Curtiaud, Anais; Ohana, Mickael; Fafi-Kremer, Samira; Schini-Kerth, Valerie; Grunebaum, Lelia; Freyssinet, Jean-Marie
title: Microparticles in COVID-19 as a link between lung injury extension and thrombosis
date: 2021-06-21
journal: ERJ Open Res
DOI: 10.1183/23120541.00954-2020
sha: 46caadceb06196bc431d2e042dfab0036a70f76b
doc_id: 1014298
cord_uid: ccdw3r99

Procoagulant microparticles are associated with the extent of lung injuries in #COVID19 and pulmonary thrombosis https://bit.ly/3eX2LPc

We identified consecutive COVID-19 patients admitted to the intensive care unit (ICU) and non-ICU units at Strasbourg University Hospital from 25 February 2020 to 19 April 2020. Blood samples were obtained in the 48 h following admission. Patients were eligible if lupus anticoagulant (LA) was positively detected and remaining plasma available. To ascertain their contribution in COVID-19 lung injuries and related coagulopathy, procoagulant MPs levels, pro-inflammatory cytokines (interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1)), and cyto-adhesins (intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1)), as markers of endothelium damage, were measured in 52 patients with COVID-19 infection and positive LA. In addition, leukocytes, platelets, fibrinogen, activated partial thromboplastin time (APTT), von Willebrand factor antigen (vWF:Ag) and D-dimers levels were determined. Control groups were age-matched and consisted of 40 non-COVID-19 patients with positive LA screened at the Haematology department for acquired coagulopathy and 20 healthy volunteers (blood donors) without any cardiovascular risk factors or significant comorbidities. Measurement of MPs procoagulant activity was performed with the ZYMUPHEN MP-Activity ELISA kit (Hyphen Biomed, Neuville-sur-Oise, France). MPs were captured on immobilised annexin V and their phosphatidylserine content measured by a prothrombinase assay using a microtitration plate reader equipped with kinetics software. In this assay, blood clotting factors (FXa, FVa, FII) and calcium concentrations were determined to ensure that phosphatidylserine is the rate-limiting parameter in the generation of soluble thrombin from prothrombin. Results were expressed as nanomolar phosphatidylserine equivalent (nmol·L −1 PhtdSerEq) by reference to a standard curve constructed with liposomes of known composition and concentration. With respect to characterisation of MPs by flow cytometry, this functional method allows the determination of MPs prothrombotic properties [4, [8] [9] [10] .

Haemostasis assays (fibrinogen, vWF:Ag, D-dimer, LA detection) were analysed on STA-R Evolution (Diagnostica Stago, Asnières-sur-Seine, France) with standard commercial reagents and protocols. The extent of COVID-19 disease on chest computed tomography (CT) was assessed as extension of pulmonary injuries as a percentage of the total lung parenchyma and classified according to the European Society of Radiology/European Society of Thoracic Imaging guidelines as minimal (stage 1 <10%), moderate (stage 2=10-25%), severe (stage 3=25-50%) and critical (stage 4 >50%). Patients with suspected acute pulmonary embolism, based on their clinical, echocardiographic or laboratory parameters had a CT pulmonary angiography performed, either at the admission or during their stay. The present study was approved by the research ethics committee of Strasbourg Hospital and written informed consent was obtained from all patients.

Among the 52 patients with COVID-19 infection and positive LA (mean age 54±20 years; male sex 78.8%), 12 patients experienced acute pulmonary embolism and 20 showed severe lung injury severity (>50%) assessed by chest CT. No baseline differences between COVID-19 patients and non-COVID-19 patients with positive LA could be identified apart from obesity (18 (34.6%) versus 3 (7.5%), p=0.002) and smoking habits (2 (3.8%) versus 7 (17.5%), p=0.029).

A stepwise increase in pro-inflammatory cytokines and cyto-adhesins levels could be seen among the three groups, with highest values measured in COVID-19 patients (figure 1a-d). Procoagulant MPs were 2.5 times higher in patients with LA as compared with healthy volunteers In the past, several reports have emphasised that circulating endothelial MPs are a reliable marker of early lung destruction in cigarette smokers [11] , pulmonary hypertension [12] and various lung diseases [13] . More recently, a study performed in microvascular lung endothelial cells and in patients with acute respiratory distress syndrome has emphasised the importance of ACE-bearing MPs as an important marker of disease severity [14] . Consistent with this paradigm, we report that procoagulant MPs are associated with the extent of lung injuries in COVID-19 and pulmonary thrombosis. Additional work is needed to confirm that MPs behave as bioactive shuttles spreading the thrombotic burden within the vasculature in SARS-CoV-2 infection. kits. For instance, patent fee for 2012 was 1902.83 EUR for France and Germany only, not including Japan and US rights. Last royalties, over 36 months (3 years) amounted to 5153 EUR, submitted to 16% taxes paid to the French tax system. Support Statement: This work was supported by the Groupe pour l'Enseignement de la Recherche Cardio-vasculaire en Alsace, France, by Fondation Coeur et Recherche and by an unrestricted research grant from Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany. Funding information for this article has been deposited with the Crossref Funder Registry.

UMR INSERM 1260, Regenerative Nanomedicine

Data collection and interpretation. S. Fafi-Kremer: Drafting of the manuscript, data collection and interpretation. V. Schini-Kerth and L. Grunebaum: Data collection and interpretation, critical revision for important intellectual content

Morel has nothing to disclose. B. Marchandot has nothing to disclose. L. Jesel has nothing to disclose. L. Sattler has nothing to disclose. A. Trimaille has nothing to disclose. A. Curtiaud has nothing to disclose

Ohana has nothing to disclose. S. Fafi-Kremer has nothing to disclose

Freyssinet reports other (royalties) from HYPHEN BioMed, during the conduct of the study; In addition, Dr. Freyssinet has a patent WO1996003655A1 with royalties paid to HYPHEN BioMed and Patent WO1996003655A1 expired several years ago

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19

Cell-derived microparticles and the lung

Microparticles, vascular function, and atherothrombosis

The significance of shed membrane particles during programmed cell death in vitro, and in vivo, in HIV-1 infection

Endothelial microparticles from acute coronary syndrome patients induce premature coronary artery endothelial cell aging and thrombogenicity: role of the Ang II/AT1 receptor/NADPH oxidase-mediated activation of MAPKs and PI3-Kinase pathways

Exosome-mediated transfer of ACE2 (angiotensin-converting enzyme 2) from endothelial progenitor cells promotes survival and function of endothelial cell

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

Protective effects of vitamin C on endothelium damage and platelet activation during myocardial infarction in patients with sustained generation of circulating microparticles

Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes

Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol

Circulating endothelial microparticles as a measure of early lung destruction in cigarette smokers

Procoagulant membrane microparticles correlate with the severity of pulmonary arterial hypertension

Extracellular vesicles in lung disease

Increase in circulating ACE-positive endothelial microparticles during acute lung injury